SB 202190
CAS: 152121-30-7
Ref. TM-T2301
25mg | 33.00 € | ||
50mg | 47.00 € | ||
100mg | 76.00 € | ||
200mg | 127.00 € | ||
1ml*10 (DMSO) | 47.00 € |
Product Information
- FHPI, SB202190
- 2,5-cyclohexadien-1-one, 4-[4-(4-fluorophenyl)-1,3-dihydro-5-(4-pyridinyl)-2H-imidazol-2-ylidene]-
- 4-(4-Fluorophenyl)-2-(4-Hydroxyphenyl)-5-(4-Pyridyl)Imidazole
- 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole
- 4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol
- 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol
- 4-[5-(4-Fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol
- Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-
- Sb 202190
- Sb202190
- See more synonyms
- phenol, 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-imidazol-2-yl]-
SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
Chemical properties
Technical inquiry about: TM-T2301 SB 202190
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.